🔴 BreakingDrug approvalRSSMay 15
Hympavzi now approved for more hemophilia patients in Europe
Hympavzi, a new hemophilia treatment made by Pfizer, has been approved in Europe for more patients. The drug helps people with hemophilia A or B who have developed inhibitors—a complication where the body fights back against standard treatments. This approval expands who can use the medicine to help them bleed less and stay healthier.
WHY IT MATTERSEuropean hemophilia patients with inhibitors now have access to Hympavzi, a subcutaneous therapy that may reduce bleeding episodes and improve quality of life compared to traditional intravenous treatments.